YLYuxia Liu

Yuxia Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuxia Liu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Silencing pain with infrared light

    by Yuxia Liu, Xiaogang Liu

  • Open Access

    Lanthanide carriers: biomedical imaging redefined

    by Yuxia Liu, Zixuan Chen, Mingyu Sui, Hongxuan Wang, Marco Bettinelli, Luís D. Carlos, Daniel Jaque, Oscar L. Malta, Jorge Méndez-Ramos, Cyrille Richard, et al.

    Lanthanide-based carriers have emerged as powerful platforms for next-generation biomedical imaging, combining unique optical and magnetic features to address key limitations of conventional agents. Owing to their 4f electron configuration, lanthanide ions provide sharp emission lines, long lifetimes, high photostability, and strong paramagnetism, enabling high-resolution, multiplexed, and deep-tissue imaging with minimal photodamage. This review surveys recent advances across optical, X-ray, and magnetic resonance modalities, focusing on how material design influences performance. We examine representative carriers, such as lanthanide-doped nanoparticles, organic complexes, and lanthanide-binding proteins, and their roles in near-infrared (NIR) imaging (long-term single-particle tracking, molecular sensing, and NIR-II modalities), X-ray imaging (contrast media, scintillators, and persistent emitters for low-dose diagnostics), and magnetic resonance imaging (chemical and biosynthetic agents with enhanced relaxivity, specificity, and safety, including targeted protein constructs). We highlight molecular engineering and surface modification strategies that boost signal and biocompatibility, and discuss emerging directions such as artificial intelligence-enabled data analysis and the integration of multimodal probes to deliver integrated anatomical and functional information. While most advances are still at the proof-of-concept stage, lanthanide carriers show great potential for bridging materials science, biophysics, and clinical needs, and are reshaping biomedical imaging toward more precise, responsive, and personalized diagnostics.


  • Open Access

    Tiny Metal Carriers Help Doctors See Inside the Body

    by Yuxia Liu, Xiaogang Liu

    Doctors often need to see inside the body without surgery. Medical imaging provides several ways to do so, helping to find disease, plan treatments, and check whether treatments are working. But imaging is difficult: signals from deep tissues can become weak, blurry, or mixed with background noise from nearby tissues. This article explains how tiny carriers that hold special metals called lanthanides could help improve imaging. Lanthanides can create useful signals, but they must be held safely so they do not harm the body. Carriers such as nanoparticles, chemical “cages”, or proteins can help protect lanthanides, control how they behave, and make their signals easier to detect. These tools could allow doctors to see diseases and body processes more clearly. Before they are widely used in patients, researchers must prove that lanthanide carriers are reliable, safe, and environmentally responsible.

  • Direct quantification of Piezo1 activation threshold through DNA-tethered extracellular force sensing

    by Mingyu Sui, Jingzhun Liu, Chaoyu Fu, Yuxia Liu, Jie Yan, Xiaogang Liu


  • Top Cited Papers

    Photophysics-Guided Upconversion Nanosystems for Sensing

    by Yuxia Liu, Jiaye Chen, Xiaogang Liu

    ConspectusPhoton upconversion, which converts low-energy near-infrared light into higher-energy emission, has emerged as a powerful tool at the intersection of photophysics, materials science, and biosensing. The nonlinear excitation, large anti-Stokes shifts, minimal background autofluorescence, high photostability, and effective tissue penetration of photon upconversion make it particularly attractive for probing biological systems under physiologically relevant conditions.Lanthanide-doped nanoparticles constitute a dominant class of upconversion systems. Encapsulation of lanthanide ions within crystalline hosts shields their 4f electronic states from environmental perturbations, enabling spectrally stable and temporally persistent emission. Nevertheless, their relatively low quantum yields under biologically safe irradiation often necessitate higher excitation power densities, which limit their in vivo applications. To address this challenge, advances in materials design, most notably core-shell architectures that regulate energy migration and suppress surface quenching, have substantially boosted upconversion efficiency and spectral tunability. Complementary surface engineering via chemical modifications has further enhanced colloid stability, biocompatibility, and targeting specificity. In parallel, optical field engineering strategies, including superlensing effects and plasmonic coupling, have expanded the functional scope of upconversion platforms beyond conventional luminescence. Together, these developments have established upconversion nanoparticles as a robust physical interface between optical excitation and biological response.In this Account, we focus on recent progress in integrating upconversion nanoparticles with diverse physical modalities for biosensing and biointerfacing. We first outline the photophysical principles underlying photon upconversion and summarize key strategies for enhancing efficiency and signal fidelity. We then survey upconversion nanoparticle-based platforms that couple optical emission with electrical, mechanical, and thermal readouts. In optical microscopy, upconversion nanoparticles enable long-term single-particle tracking of neuronal transport and support super-resolution imaging through nonlinear emission processes and surface-migration depletion. When interfaced with electrophysiological measurements, these nanoparticles allow real-time monitoring of transmembrane water transport including flux through ion channels. Upconversion-assisted optogenetics further enables noninvasive neuromodulation without implanting optical fibers. Besides optical and electrical modalities, upconversion nanoparticles have been applied to force sensing over a wide dynamic range and to subcellular thermometry with high spatial precision. Incorporation of upconversion nanoparticles into device architectures extends these capabilities to stochastic photoluminescence encoding, infrared vision through retinal nanoantennas, and biocompatible contact lenses for near-infrared color perception.Looking ahead, the main challenges include further improving quantum yield under biologically permissible excitation, reducing excitation power requirements while maintaining high brightness, establishing long-term biosafety, and advancing toward clinical translation. Emerging directions such as data-driven materials design, artificial intelligence-guided optimization, and integration with regenerative medicine and microrobotics may help overcome these hurdles. By uniting advances in photophysical control with biological sensing and actuation, upconversion nanoplatforms hold strong potential to transform imaging, diagnostics, and therapeutic intervention.


  • Top Cited Papers

    Solvent-mediated analgesia via the suppression of water permeation through TRPV1 ion channels

    by Yuxia Liu, Yuanyuan He, Jiahuan Tong, Shengyang Guo, Xinyu Zhang, Zichao Luo, Linlin Sun, Chao Chang, Bilin Zhuang, Xiaogang Liu

    Activation of the ion channel transient receptor potential vanilloid 1 (TRPV1), which is integral to pain perception, leads to an expansion of channel width, facilitating the passage of cations and large organic molecules. However, the permeability of TRPV1 channels to water remains uncertain, owing to a lack of suitable tools to study water dynamics. Here, using upconversion nanophosphors to discriminate between H2O and D2O, by monitoring water permeability across activated TRPV1 at the single-cell and single-molecule levels, and by combining single-channel current measurements with molecular dynamics simulations, we show that water molecules flow through TRPV1 and reveal a direct connection between water migration, cation flow and TRPV1 functionality. We also show in mouse models of acute or chronic inflammatory pain that the administration of deuterated water suppresses TRPV1 activity, interrupts the transmission of pain signals and mitigates pain without impacting other neurological responses. Solvent-mediated analgesia may inspire alternative options for pain management.


  • Open Access

    Single-point mutated lanmodulin as a high-performance MRI contrast agent for vascular and kidney imaging

    by Yuxia Liu, Duyang Gao, Yuanyuan He, Jing Ma, Suet Yen Chong, Xinyi Qi, Hui Jun Ting, Zichao Luo, Zhigao Yi, Jingyu Tang, et al.

    Magnetic resonance imaging contrast agents can enhance diagnostic precision but often face limitations such as short imaging windows, low tissue specificity, suboptimal contrast enhancement, or potential toxicity, which affect resolution and long-term monitoring. Here, we present a protein contrast agent based on lanmodulin, engineered with a single-point mutation at position 108 from N to D to yield maximum gadolinium binding sites. After loading with Gd3+ ions, the resulting protein complex, LanND-Gd, exhibits efficient renal clearance, high relaxivity, and prolonged renal retention compared to commercial agents. LanND-Gd enables high-performance visualization of whole-body structures and brain vasculature in male mice at a resolution finer than one hundred micrometers. In male ischemia mouse models, LanND-Gd also improves kidney dysfunction monitoring while minimizing risks of neural toxicity or immunogenic reactions. This protein-based contrast agent offers superior image quality, improved biocompatibility, and extended imaging timeframes, promising significant advancements in magnetic resonance-based diagnostics and patient outcomes.


  • Retracted
    Open Access

    Long Non-Coding RNA AGAP2-AS1/miR-628-5p/PTN Axis Modulates Proliferation, Migration, Invasion, and Apoptosis of Glioma Cells

    by Yang Yan, Yiping Wang, Yuxia Liu, Tao Chen, Yaoli Zhu, Huiqing Li, Fangen Kong

    Purpose: Long non-coding RNAs (lncRNAs) have been reported to be involved in a variety of cancers, including glioma. However, the exact role and underlying mechanism of lncRNA AGAP2 antisense RNA 1 (AGAP2-AS1) in glioma have not yet been fully elucidated. Methods: The expression levels of AGAP2-AS1, microRNA-628-5p (miR-628-5p) and pleiotrophin (PTN) were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Cell proliferation, apoptosis, migration and invasion were detected by Cell Counting Kit-8 (CCK-8) assay, flow cytometry, transwell assay, respectively. Western blot assay was used to detect the protein level of PTN. The interaction between miR-628-5p and AGAP2-AS1 or PTN was predicted by bioinformatics software and confirmed by the dual-luciferase reporter and RNA Immunoprecipitation (RIP) assays. Murine xenograft model was established to confirm the role of AGAP2-AS1 in glioma progression in vivo. Results: AGAP2-AS1 expression was upregulated in glioma tissues and cells. Knockdown of AGAP2-AS1 inhibited the proliferation, migration and invasion, but facilitated apoptosis in glioma cells. Moreover, AGAP2-AS1 could directly bind to miR-628-5p and its overexpression reversed the anti-tumor effect of miR-628-5p restoration on the progression of glioma cells. In addition, miR-628-5p directly targeted PTN and its inhibition abolished the inhibitory effect of PTN knockdown on the progression of glioma cells. Furthermore, AGAP2-AS1 functioned as a competing endogenous RNA (ceRNA) by sponging miR-628-5p to modulate PTN expression. Besides, AGAP2-AS1 depletion reduced tumor growth by upregulating miR-628-5p and downregulating PTN. Conclusion: AGAP2-AS1 knockdown suppressed cell proliferation, migration and invasion but promoted cell apoptosis in glioma cells by regulating miR-628-5p/PTN axis, providing novel avenues for treatment of glioma.